EGFR and type 1 diabetes mellitus: Upregulated pathways included mannose-type O-glycan biosynthesis, graft-versus-host disease, N-glycan biosynthesis, allograft rejection, type I diabetes mellitus, autoimmune thyroid disease, acute myeloid leukemia, renal cell carcinoma, antigen processing and presentation, ErbB signaling, axon guidance, T cell receptor signaling, and human immunodeficiency virus 1 infection, among others (Figure 4C).